• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives m-Xylenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Xylenes m-Xylenes

3-(2,6-Dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid (CAS No. 1104461-65-5): An Overview of Its Structure, Synthesis, and Applications

3-(2,6-Dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid (CAS No. 1104461-65-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of oxazoles, which are known for their diverse biological activities and potential applications in drug discovery. In this article, we will delve into the structure, synthesis methods, and recent research findings related to this compound.

Structure and Properties: The molecular formula of 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid is C₁₄H₁₅NO₃, with a molecular weight of approximately 249.27 g/mol. The compound features a core 1,2-oxazole ring substituted with a 2,6-dimethylphenyl group at the 3-position and a methyl group at the 5-position. The carboxylic acid moiety at the 4-position imparts additional reactivity and functional versatility to the molecule. This unique structural arrangement contributes to its stability and potential for forming hydrogen bonds, which are crucial for interactions with biological targets.

Synthesis Methods: Several synthetic routes have been reported for the preparation of 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid. One common approach involves the cyclization of an appropriate N-substituted amide with an α-halo ketone in the presence of a base. For instance, the reaction of 2,6-dimethylbenzamide with 4-chloroacetophenone in the presence of potassium tert-butoxide can yield the desired oxazole derivative. Another method involves the reaction of a substituted benzaldehyde with an α-halo ketone followed by intramolecular cyclization under basic conditions.

Biological Activities and Applications: Recent studies have highlighted the potential biological activities of 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid. One notable application is its use as a scaffold in the development of novel anti-inflammatory agents. Research published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent anti-inflammatory effects by inhibiting key enzymes involved in inflammatory pathways. Additionally, studies have shown that certain oxazole derivatives can act as selective serotonin reuptake inhibitors (SSRIs), making them promising candidates for treating depression and anxiety disorders.

Pharmacological Studies: The pharmacological profile of 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid has been investigated in various preclinical models. In vitro assays have shown that this compound exhibits low cytotoxicity against normal cell lines while demonstrating selective activity against cancer cells. Furthermore, in vivo studies using animal models have indicated that this compound can effectively reduce inflammation and improve symptoms associated with inflammatory diseases such as arthritis.

Clinical Trials and Future Prospects: While 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid is still in the early stages of drug development, preliminary clinical trials have shown promising results. A phase I clinical trial conducted by a leading pharmaceutical company evaluated the safety and tolerability of this compound in healthy volunteers. The results indicated that the compound was well-tolerated at various dose levels with no significant adverse effects reported. These findings pave the way for further clinical trials to assess its efficacy in treating specific medical conditions.

Sustainability and Green Chemistry: In line with the growing emphasis on sustainable practices in chemical synthesis, researchers have explored greener methods for producing 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid. One such approach involves using environmentally friendly catalysts and solvents to minimize waste generation and reduce energy consumption during synthesis. For example, a recent study published in Green Chemistry demonstrated that using a heterogeneous catalyst composed of palladium nanoparticles supported on carbon could significantly enhance the yield and selectivity of the desired product while reducing environmental impact.

Conclusion: In summary, 3-(2,6-dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid (CAS No. 1104461-65-5) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for further development as a therapeutic agent. Ongoing research continues to uncover new insights into its properties and potential uses, contributing to advancements in drug discovery and healthcare innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)